GGHC
ASMB icon

Gilder Gagnon Howe & Co’s Assembly Biosciences ASMB Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-5,135
Closed -$1.19M – 258
2015
Q2 		$1.19M Buy
+5,135
New +$991K 0.02% 210

Other funds holding ASMB

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Gilder Gagnon Howe & Co's ASMB Position: Q3 2015 in Review

Gilder Gagnon Howe & Co sold out of Assembly Biosciences (ASMB) in Q3 2015, closing a stake of 5,135 shares — an estimated $1.19M sold.

Gilder Gagnon Howe & Co first reported a position in ASMB in Q2 2015 and held it in 1 quarter. The position peaked at $1.19M in Q2 2015. 52 funds tracked by Wall St. Rank hold ASMB as of Q3 2015.

  • Gilder Gagnon Howe & Co reported no remaining Assembly Biosciences position as of Q3 2015 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 5,135 Assembly Biosciences shares in Q3 2015, an estimated $1.19M.
  • Gilder Gagnon Howe & Co first reported a position in Assembly Biosciences in Q2 2015 and held it in 1 quarter.
  • Gilder Gagnon Howe & Co's Assembly Biosciences position peaked at $1.19M in Q2 2015.
  • 52 funds tracked by Wall St. Rank held Assembly Biosciences as of Q3 2015.

Based on Gilder Gagnon Howe & Co's 13F filing for Q3 2015, filed 9 Nov 2015.